NZ613370A - Combinations for treating hcv - Google Patents

Combinations for treating hcv

Info

Publication number
NZ613370A
NZ613370A NZ613370A NZ61337011A NZ613370A NZ 613370 A NZ613370 A NZ 613370A NZ 613370 A NZ613370 A NZ 613370A NZ 61337011 A NZ61337011 A NZ 61337011A NZ 613370 A NZ613370 A NZ 613370A
Authority
NZ
New Zealand
Prior art keywords
hcv
combinations
compositions
treating hcv
potential
Prior art date
Application number
NZ613370A
Other languages
English (en)
Inventor
William E Delaney
John O Link
Hongmei Mo
David W Oldach
Adrian S Ray
William J Watkins
Cheng Yong Yang
Weidong Zhong
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of NZ613370A publication Critical patent/NZ613370A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NZ613370A 2010-12-20 2011-12-08 Combinations for treating hcv NZ613370A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061425194P 2010-12-20 2010-12-20
US201161495841P 2011-06-10 2011-06-10
PCT/US2011/064017 WO2012087596A1 (en) 2010-12-20 2011-12-08 Combinations for treating hcv

Publications (1)

Publication Number Publication Date
NZ613370A true NZ613370A (en) 2015-05-29

Family

ID=45446195

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ613370A NZ613370A (en) 2010-12-20 2011-12-08 Combinations for treating hcv

Country Status (10)

Country Link
US (3) US20130273005A1 (https=)
EP (1) EP2654900A1 (https=)
JP (2) JP5891241B2 (https=)
AR (1) AR084237A1 (https=)
AU (1) AU2011349844B2 (https=)
CA (1) CA2822037A1 (https=)
NZ (1) NZ613370A (https=)
TW (2) TW201701876A (https=)
UY (1) UY33797A (https=)
WO (1) WO2012087596A1 (https=)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
PT3309157T (pt) * 2009-05-13 2019-12-02 Gilead Pharmasset Llc Compostos antivirais
BR122020020745B8 (pt) 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
AU2011349844B2 (en) 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
CA2873315A1 (en) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) * 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8927741B2 (en) * 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
KR102001280B1 (ko) 2012-10-08 2019-07-17 아이데닉스 파마슈티칼스 엘엘씨 Hcv 감염에 대한 2'-클로로 뉴클레오시드 유사체
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN104140417B (zh) * 2014-06-11 2016-04-06 苏州景泓生物技术有限公司 合成gs5885用的中间体的先期化合物的合成方法
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
CA2960436C (en) * 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
BR112017005100A2 (pt) * 2014-09-16 2017-12-05 Gilead Sciences Inc métodos de preparação de moduladores de receptores do tipo toll
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SI3349758T1 (sl) 2015-09-16 2022-08-31 Gilead Sciences, Inc. Postopki za zdravljenje okužb z virusom arenaviridae
CN105646626B (zh) * 2016-02-24 2018-04-24 贵州理工学院 一种高收率索氟布韦的合成方法
JP6551263B2 (ja) 2016-03-02 2019-07-31 株式会社デンソー ヘッドアップディスプレイ装置
CN105669358A (zh) * 2016-03-17 2016-06-15 中国药科大学 多取代芴衍生物的氟化方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN105968040B (zh) * 2016-06-29 2019-02-05 爱斯特（成都）生物制药股份有限公司 一种雷迪帕韦中间体的制备方法
CN106432197B (zh) * 2016-09-07 2019-12-10 上海众强药业有限公司 一种雷迪帕韦中间体单对甲苯磺酸盐、其晶型及其制备方法
CN115477679A (zh) 2017-02-01 2022-12-16 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
AU2018262501B2 (en) * 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP7401456B2 (ja) 2018-11-14 2023-12-19 第一三共株式会社 抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
EP3670488A1 (en) 2018-12-18 2020-06-24 Basf Se Bi- and tricyclic ketones for use as aroma chemicals
AU2020246448A1 (en) 2019-03-25 2021-10-14 Daiichi Sankyo Company, Limited Anti-HER2 antibody-pyrrolobenzodiazepine derivative conjugate
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
TWI841715B (zh) 2019-03-27 2024-05-11 日商第一三共股份有限公司 抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途
EP3946611A2 (en) 2019-03-31 2022-02-09 Yeda Research and Development Co. Ltd Anti-viral and anti-tumoral compounds
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CN113214262B (zh) * 2020-02-05 2023-07-07 华创合成制药股份有限公司 一种含有胍基的化合物及其制备方法和用途
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI884403B (zh) 2020-02-18 2025-05-21 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
AU2021296841B2 (en) 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
WO2022038539A2 (en) * 2020-08-18 2022-02-24 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
SI4204421T1 (sl) 2020-08-27 2024-07-31 Gilead Sciences, Inc., Spojine in postopki za zdravljenje virusnih okužb
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3219397A1 (en) 2021-05-21 2022-11-24 Gilead Sciences, Inc. Tetracyclic compounds for the treatment of zika virus infection
CA3220903A1 (en) 2021-05-21 2022-11-24 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors
TW202317145A (zh) * 2021-06-17 2023-05-01 美商亞堤製藥公司 有利之抗hcv組合療法
KR20240022574A (ko) 2021-06-17 2024-02-20 아테아 파마슈티컬즈, 인크. 유리한 항-hcv 조합 요법
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US4614719A (en) 1982-04-30 1986-09-30 Yamasa Shoyu Kabushiki Kaisha Process for producing ribavirin
EP2345657A1 (en) * 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
CA2627839C (en) 2005-11-02 2014-08-19 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
EP2038290B1 (en) * 2006-07-07 2013-09-04 Gilead Sciences, Inc. Modulators of toll-like receptor 7
DE602007004220D1 (de) * 2006-07-07 2010-02-25 Leuven K U Res & Dev Neue pyridazinverbindung und ihre verwendung
TW200819460A (en) * 2006-07-07 2008-05-01 Gilead Sciences Inc Antiviral phosphinate compounds
NZ582096A (en) * 2007-06-29 2012-05-25 Gilead Sciences Inc Antiviral compounds that inhibit hepatitis c virus (hcv)
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
AP2009005073A0 (en) 2007-06-29 2009-12-31 Gilead Sciences Inc Antiviral compounds
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
ES2398684T3 (es) * 2008-04-23 2013-03-21 Gilead Sciences, Inc. Análogos de carbanucleósido para el tratamiento antiviral
US7921612B2 (en) 2008-08-31 2011-04-12 United Construction Products, Inc. Method and device for supporting a structure
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
PT3309157T (pt) * 2009-05-13 2019-12-02 Gilead Pharmasset Llc Compostos antivirais
PE20120995A1 (es) 2009-09-21 2012-08-01 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
AP3576A (en) 2010-01-15 2016-02-08 Gilead Sciences Inc Inhibitors of flaviviridae viruses
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
US20110306541A1 (en) 2010-06-10 2011-12-15 Gilead Sciences, Inc. Methods for treating hcv
KR101995598B1 (ko) 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
PE20171624A1 (es) 2010-09-20 2017-11-02 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
AU2011349844B2 (en) 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv

Also Published As

Publication number Publication date
TW201701876A (zh) 2017-01-16
JP2014505045A (ja) 2014-02-27
CA2822037A1 (en) 2012-06-28
US20170042961A1 (en) 2017-02-16
AR084237A1 (es) 2013-05-02
JP2016040331A (ja) 2016-03-24
EP2654900A1 (en) 2013-10-30
JP6162206B2 (ja) 2017-07-12
US20150141353A1 (en) 2015-05-21
UY33797A (es) 2012-07-31
JP5891241B2 (ja) 2016-03-22
AU2011349844B2 (en) 2017-06-01
TW201306841A (zh) 2013-02-16
US20130273005A1 (en) 2013-10-17
WO2012087596A1 (en) 2012-06-28
US9452154B2 (en) 2016-09-27

Similar Documents

Publication Publication Date Title
NZ613370A (en) Combinations for treating hcv
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MX2009011064A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
NZ607996A (en) Substituted nucleotide analogs
WO2012083048A3 (en) Anti-viral compounds
WO2012083053A3 (en) Anti-viral compounds
WO2013040492A3 (en) Methods for treating hcv
HK1203075A1 (en) Substituted phosphorothioate nucleotide analogs
MY195289A (en) Anti IL-36R Antibodies
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
TW200720285A (en) Nucleoside compounds for treating viral infections
WO2013074386A3 (en) Hcv ns3 protease inhibitors
MY155950A (en) Anti-cd40 antibodies
MX363189B (es) Productos químicos, composiciones y métodos para tratamiento y prevención de infecciones de virus orthopox y enfermedades asociadas.
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
WO2012083061A3 (en) Anti-viral compounds
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
PH12013502190A1 (en) Hepatitis c virus inhibitors
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
WO2010021717A3 (en) Hcv protease inhibitors
WO2012083058A3 (en) Anti-viral compounds

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2016 BY COMPUTER PACKAGES INC

Effective date: 20151118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2017 BY COMPUTER PACKAGES INC

Effective date: 20161118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2018 BY COMPUTER PACKAGES INC

Effective date: 20171118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2019 BY COMPUTER PACKAGES INC

Effective date: 20181120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2020 BY COMPUTER PACKAGES INC

Effective date: 20191119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2021 BY CPA GLOBAL

Effective date: 20201022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2022 BY CPA GLOBAL

Effective date: 20211022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2023 BY CPA GLOBAL

Effective date: 20221027

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2024 BY CPA GLOBAL

Effective date: 20231026

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241101

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251024